| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Preclinical Research and Experimental Development, SUGEN, Inc., South San Francisco, CA; 2 Discovery Research Oncology, Pharmacia Corporation, Nerviano, Italy; 3 Department of Oncology Pharmacology, Pharmacia Corporation, St. Louis, MO; 4 Oncology Department, Mario Negri Institute of Pharmacological Research, Milan, Italy
Requests for reprints: Tinya Abrams, Preclinical Research and Experimental Development, SUGEN, Inc., 230 East Grand Avenue, South San Francisco, CA 94080. Phone: (650) 837-3655; Fax: (650) 837-3308. Email: tinya-abrams{at}sugen.com
SU11248 is an oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities through targeting platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT, and FLT3, the first three of which are expressed in human breast cancer and/or its supporting tissues. The purpose of the present studies was to demonstrate the potent anticancer activity of SU11248 alone or in combination with conventional cytotoxic agents against several distinct preclinical models of breast cancer. SU11248 was administered as a monotherapy to (1) mouse mammary tumor virus-v-Ha-ras mice and 7,12-dimethylbenz(a)anthracene-treated rats bearing mammary tumors and (2) mice bearing human breast cancer xenografts of s.c. MX-1 tumors and osseous metastasis of a MDA-MB-435-derived cell line (435/HAL-Luc). SU11248 was also administered in combination with docetaxel both in xenograft models and in combination with 5-fluorouracil and doxorubicin in the MX-1 model. SU11248 treatment potently regressed growth of mammary cancers in mouse mammary tumor virus-v-Ha-ras transgenic mice (82% regression) and 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats (99% regression at the highest dose; P < 0.05 for both). This agent also inhibited MX-1 tumor growth by 52%, with markedly enhanced anticancer effects when administered in combination with docetaxel, 5-fluorouracil, or doxorubicin compared with either agent alone (P < 0.05). SU11248 treatment in combination with docetaxel effectively prolonged survival of mice, with 435/HAL-Luc cancer xenografts established in bone compared with either agent alone (P < 0.05). These results demonstrate that SU11248 is effective in preclinical breast cancer models and suggest that it may be useful in the treatment of breast cancer in the clinic.
1 L. J. Murray, T. J. Abrams, K. R. Long, T. J. Ngai, L. M. Olson, M. D. Pagel, W. Hong, P. K. Keast, J. A. Brassard, A. M. O'Farrell, J. M. Cherrington, and N. K. Pryer. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model, submitted for publication.
Received 5/ 1/03; revised 6/25/03; accepted 7/31/03.
This article has been cited by other articles:
|
|
 |
|
  F. Navid, R. Christensen, P. Minkin, C. F Stewart, W. L Furman, and S. Baker Stability of Sunitinib in Oral Suspension Ann. Pharmacother., July 1, 2008; 42(7): 962 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Hodkinson, A. MacKinnon, and T. Sethi Targeting Growth Factors in Lung Cancer Chest, May 1, 2008; 133(5): 1209 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. DePrimo, et al. Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane J. Clin. Oncol., April 10, 2008; 26(11): 1810 - 1816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Zhou, P. Guo, and J. M. Gallo Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide Clin. Cancer Res., March 1, 2008; 14(5): 1540 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Saltz, L. S. Rosen, J. L. Marshall, R. J. Belt, H. I. Hurwitz, S. G. Eckhardt, E. K. Bergsland, D. G. Haller, A. C. Lockhart, C. M. Rocha Lima, et al. Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy J. Clin. Oncol., October 20, 2007; 25(30): 4793 - 4799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mannavola, P. Coco, G. Vannucchi, R. Bertuelli, M. Carletto, P. G. Casali, P. Beck-Peccoz, and L. Fugazzola A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3531 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Q.M. Chow and S. G. Eckhardt Sunitinib: From Rational Design to Clinical Efficacy J. Clin. Oncol., March 1, 2007; 25(7): 884 - 896. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ciomei, V. Croci, A. Ciavolella, D. Ballinari, and E. Pesenti Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model. Clin. Cancer Res., May 1, 2006; 12(9): 2856 - 2861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clin. Cancer Res., March 15, 2006; 12(6): 1839 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Faivre, C. Delbaldo, K. Vera, C. Robert, S. Lozahic, N. Lassau, C. Bello, S. Deprimo, N. Brega, G. Massimini, et al. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer J. Clin. Oncol., January 1, 2006; 24(1): 25 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Motzer, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. A. Figlin, M. S. Ginsberg, S. T. Kim, C. M. Baum, S. E. DePrimo, et al. Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma J. Clin. Oncol., January 1, 2006; 24(1): 16 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Marzola, A. Degrassi, L. Calderan, P. Farace, E. Nicolato, C. Crescimanno, M. Sandri, A. Giusti, E. Pesenti, A. Terron, et al. Early Antiangiogenic Activity of SU11248 Evaluated In vivo by Dynamic Contrast-Enhanced Magnetic Resonance Imaging in an Experimental Model of Colon Carcinoma Clin. Cancer Res., August 15, 2005; 11(16): 5827 - 5832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Schneider and K. D. Miller Angiogenesis of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1782 - 1790. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fiedler, H. Serve, H. Dohner, M. Schwittay, O. G. Ottmann, A.-M. O'Farrell, C. L. Bello, R. Allred, W. C. Manning, J. M. Cherrington, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease Blood, February 1, 2005; 105(3): 986 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cain, J. L. Grisolano, A. D. Laird, and M. H. Tomasson Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657 Blood, July 15, 2004; 104(2): 561 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H G Augustin Translating angiogenesis research into the clinic: the challenges ahead Br. J. Radiol., December 1, 2003; 76(suppl_1): S3 - S10. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
